Tuesday 13 October 2026
Export CAPR’s income statement to Excel — free account
Capricor Therapeutics, Inc.
CAPR Healthcare Biotechnology
Capricor Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22.3 million, down 11.5% from fiscal 2023. In the quarter to June 2026, revenue fell 7.92%, EPS fell 22.8% and free cash flow fell 72.9%, each against the same quarter a year earlier.
6.93
0.54
−7.23%
Follow CAPR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
7.22 | 8.28 | 8.88 | 3.50 | |
Current Ratio |
7.35 | 8.42 | 9.01 | 3.59 | |
Net Debt/EBITDA |
5.50 | 7.61 | 11.10 | 3.82 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.77 | 0.86 | 0.78 | 0.80 | |
Capex/Depreciation |
17.54 | (61.06) | 508.40 | (8.10) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.54) | (0.51) | (0.51) | (0.43) | |
Capex per Share |
(0.10) | (0.19) | 5.50 | (0.09) | |
Free Cash Flow per Share |
(0.64) | (0.70) | 4.99 | (0.52) | |
Cash per Share |
4.11 | 4.85 | 6.84 | 2.16 | |
Shareholders Equity per Share |
4.25 | 4.85 | 6.58 | 1.83 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.25 | 4.85 | 6.58 | 1.83 | |
Free Cash Flow |
(37.29) | (40.00) | 231.90 | (23.70) | |
Working Capital |
209.17 | 249.45 | 287.10 | 72.80 | |
Capital Expenditures |
(5.81) | (10.75) | 255.47 | (4.01) | |
Net Current Asset Value |
119.61 | 235.51 | 272.78 | 58.38 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | 5.21 | 0.23 | |
Average Payables |
3.95 | 4.59 | 2.47 | 4.63 | |
Average Assets |
251.15 | 240.02 | 263.22 | 109.69 | |
Average Common Equity |
175.60 | 203.17 | 225.63 | 76.07 |
Columns are period end dates